Bioreactor Market

Market Overview:

The global bioreactor market size reached US$ 7.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 18.6 Billion by 2032, exhibiting a growth rate (CAGR) of 10.9% during 2024-2032.

A bioreactor refers to a fermentation vessel, wherein biological reactions are executed for developing enzymes and various organisms, including bacteria, animal cells and yeast, under controlled conditions. It aids in producing several pharmaceuticals, such as vaccines and monoclonal antibodies, maintaining the inhomogeneous state of the cells to obtain the desired output, and monitoring the environmental conditions for promoting the cell formation process. On account of these properties, a bioreactor is extensively used by biopharmaceutical companies, research and development (R&D) institutions, and contract research organizations (CROs). At present, it is commercially available in glass, stainless steel, and single-use material types.

Bioreactor Market Trends:

The global bioreactor market is majorly driven by the increasing prevalence of various chronic diseases, such as cancer and diabetes, especially amongst the steadily rising geriatric population. In line with this, the growing need for preventive vaccines, particularly during the sudden outbreak of the coronavirus disease (COVID-19) pandemic, have prompted several pharmaceutical companies to considerably invest in research and development (R&D) activities to extend their production capacities. This, in turn, is inflating the overall sales of bioreactors across the globe. Additionally, significant technological advancements, such as the introduction of single-use bioreactors (SUBs) for optimizing the quality, flexibility, and scalability of microorganisms’ formation operations with minimal cost and energy requirements, are positively stimulating the market growth. Apart from this, increasing biopharmaceuticals manufacturing capacities across developing nations, along with the rising demand for bioreactors that support modern, evolving, high-cell density, and intensified clinical processes requiring high oxygen transfer and great carbon dioxide (CO2) removal are propelling the market growth. Other factors, such as rapid expansion in the pharmaceutical and biologics sectors, the escalating need for effective treatment drugs, and the increasing awareness among consumers regarding the formulation and availability of personalized medicines, are contributing to the market growth significantly.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global bioreactor market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on type, usage, scale and control type.

Breakup by Type:

• Glass
• Stainless Steel
• Single-Use
   

Breakup by Usage:

• Lab-Scale Production
• Pilot-Scale Production
• Full-Scale Production
   

Breakup by Scale:

• 5L-20L
• 20L-200L
• 200L-1500L
• Above 1500L
   

Breakup by Control Type:

• Manual
• Automated
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 2mag AG, bbi-biotech GmbH, Bioengineering AG, Eppendorf SE, Getinge AB, Infors AG, Merck KGaA, Pall Corporation (Danaher Corporation), Sartorius AG, Solaris Biotechnology Srl and Thermo Fisher Scientific Inc.

Report Coverage: